Aging, MicroRNAs, and Heart Failure
Introduction
Aging is a major risk factor for cardiovascular diseases (CVD), which represent more than 30% of all deaths worldwide. As the average human lifespan continues to increase, the prevalence of age-associated diseases including heart failure (HF), hypertension, and diabetes is assuming epidemic proportions.
Aging is characterized by the decline of the physiological functions necessary for survival and reproduction. During aging, a progressive deterioration of cellular processes occurs in all tissues and all cell functions are involved in association with distinct biologic characteristics, including genomic stability due to the accumulation of DNA damage and impairment of DNA repair1; continuous shortening of telomeres2; variations in control of gene expression, such as epigenetic and alternative splicing3, 4; cellular senescence5; dysfunctions in mitochondria metabolism6 and protein homeostasis7; and enhanced oxidative stress.8
Aging per se modifies myocardial and vascular function even in the absence of clinical disease. The aging heart exhibits progressive structural and functional changes such as left ventricular hypertrophy, which is associated with a delay in ventricular relaxation, and changes in diastolic intracellular calcium dynamics (Fig 1A). Both heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) are very common in older persons and frequently coexist in the same patient. Specifically, HFpEF affects approximately 70% of elderly individuals with heart failure9; in fact, at the time of diagnosis, most of the patients with HFpEF are more than 60 years old10 and is more common in women than in men with a 2:1 ratio.9
It is noteworthy that the presence of diastolic dysfunction associated to a left ventricular ejection fraction >50% is not diagnostic for HFpEF and that clinical evidence of HF is also required. Mechanisms responsible for HFpEF are poorly characterized, although there is some evidence to support a role for low-grade inflammation,11 microvascular endothelial dysfunction,12, 13 cardiomyocyte hypertrophy,14 and enhanced fibrosis,15 ultimately leading to an increase in cardiac stiffness and impaired relaxation.16 Further, certain conditions, including hypertension,17 obesity,18 and diabetes mellitus,19 are frequent comorbidities associated with HFpEF. Elucidation of the mechanisms responsible for HFpEF is a major health priority, not only because of the large number of patients involved but also because therapeutic strategies are limited to diuretics and optimal fluid balance. This is in stark contrast to the large array of pharmacologic and nonpharmacologic treatment options in patients with HFrEF.
Section snippets
microRNAs’ Function and CVD
microRNAs (miRNAs) are short noncoding RNAs, approximately 22 nucleotides long, that regulate the expression of miRNA targets in a sequence specific manner, through the induction of miRNA degradation or translational repression.20 miRNAs modulate a variety of important cell functions including stem cell self-renewal, cell proliferation, apoptosis, metabolism, and oxidative stress,21 and have been recently considered relevant regulators of cellular senescence and aging.22 Numerous studies have
miRNAs in Aging and HF
In this review we will discuss miRNAs that may be involved in HF and examine separately miRNAs that exhibit an age-dependent modulation in the heart, in tissues other than the heart and miRNAs that may help differentiate HFpEF vs HFrEF.
Conclusions
Literature discussed in this review shows that some age-dependent miRNAs play a key role in HFrEF and suggest that they may be important therapeutic targets to improve heart function, either via their downmodulation or overexpression. Further, there are several reports that have examined age-modulated miRNAs in HF but have not established whether age-dependent changes in expression of these miRNAs occurred also in the heart. We summarized the effect of miRNAs modulated by aging and senescence
References (125)
- et al.
The role of DNA damage and repair in aging through the prism of Koch-like criteria
Ageing Res Rev
(2013) - et al.
Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities
Am J Pathol
(2012) - et al.
Inflammatory markers and incident heart failure risk in older adults: the Health ABC (health, aging, and body composition) study
J Am Coll Cardiol
(2010) - et al.
Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction
JACC Heart Fail
(2016) - et al.
Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction
J Am Coll Cardiol
(2011) - et al.
Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction
J Am Coll Cardiol
(2011) MicroRNAs: genomics, biogenesis, mechanism, and function
Cell
(2004)- et al.
MicroRNAs in stress signaling and human disease
Cell
(2012) - et al.
Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients
Int J Cardiol
(2013) - et al.
miR-21 suppression prevents cardiac alterations induced by d-galactose and doxorubicin
J Mol Cell Cardiol
(2018)
miR-22 in cardiac remodeling and disease
Trends Cardiovasc Med
Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study
Int J Cardiol
miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling
Mol Ther
Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy
J Am Coll Cardiol
Up-regulation of key microRNAs, and inverse down-regulation of their predicted oxidative phosphorylation target genes, during aging in mouse brain
Neurobiol Aging
Analysis of Rab1 function in cardiomyocyte growth
Methods Enzymol
Murine microRNAs implicated in liver functions and aging process
Mech Ageing Dev
MicroRNA-214 provokes cardiac hypertrophy via repression of EZH2
Biochem Biophys Res Commun
The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214
Mol Ther Nucleic Acids
Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging
Nat Med
Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing
Aging Cell
Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs
Aging Cell
The essence of senescence
Genes Dev
Mitochondria and the autophagy-inflammation-cell death axis in organismal aging
Science
Mitochondria and cardiovascular aging
Circ Res
Gender-related differences in heart failure with preserved ejection fraction
Sci Rep
Systolic and diastolic heart failure in the community
JAMA
Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction
Circ Heart Fail
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction
Circulation
The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview
Arch Intern Med
Obesity and the risk of heart failure
N Engl J Med
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications
Endocr Rev
MicroRNAs and their roles in aging
J Cell Sci
Functional evolution of cardiac microRNAs in heart development and functions
Mol Biol Evol
microRNAs: promising biomarkers and therapeutic targets of acute myocardial ischemia
Curr Vasc Pharmacol
The multifactorial nature of microRNAs in vascular remodelling
Cardiovasc Res
Oxidative stress and microRNAs in vascular diseases
Int J Mol Sci
Extracellular/circulating microRNAs and their potential role in cardiovascular disease
Am J Cardiovasc Dis
Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases
RNA Biol
Circulating microRNAs as stable blood-based markers for cancer detection
Proc Natl Acad Sci
Characterization of extracellular circulating microRNA
Nucleic Acids Res
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma
Proc Natl Acad Sci U S A
Circulating miRNAs: cell-cell communication function?
Front Genet
Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles
Annu Rev Cell Dev Biol
Biological properties of extracellular vesicles and their physiological functions
J Extracell Vesicles
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation
PLoS Biol
A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure
Nat Commun
miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging
Aging Cell
MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure
Aging Cell
MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure
Sci Rep
Cited by (14)
Potential regulatory role of epigenetic modifications in aging-related heart failure
2024, International Journal of CardiologyMulti-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
2023, Journal of Translational MedicineExploring the potential of microRNA as a diagnostic tool for gestational diabetes
2023, Journal of Translational MedicineCellular Senescence in Cardiovascular Diseases: From Pathogenesis to Therapeutic Challenges
2023, Journal of Cardiovascular Development and Disease
Source of funding: This work was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health to M.C.F., E.G.L., and M.C.C. and by the Italian Ministry of Health RF-2016-02362708 to A.M., S.B., and M.C.C.
- 1
These authors contributed equally to this work.